Using the 5hmC-Seal technique, scientists identify healthy individuals from patients with WHO II-III gliomas and GBM and not be affected by glioma-related pathological features, such as Isocitrate Dehydrogenase [NADP (+)] 1 (IDH1) mutation (Cai et al., 2021). Here, IDH1 is linked to glioblastoma.